Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.005
Sell
RSI(14)
36.808
Neutral
STOCH(KDJ)(9,3,3)
28.730
Neutral
ATR(14)
0.084
Low Volatility
CCI(14)
-104.991
Sell
Williams %R
85.418
Oversold
TRIX(12,20)
-1.400
Sell
StochRSI(14)
38.467
Buy
Search
BioXcel Therapeutics Inc
BTAIAdd to Watchlist
0.808USD
+0.015+1.92%
Close 07-31 16:00（ET）Quotes delayed by 15 min
21.88MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+1.92%
5 Days
-4.66%
1 Month
-42.70%
6 Months
-49.18%
Year to Date
-49.50%
1 Year
-38.32%
Key Figures
0.794Open
0.840High
499.49KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.84%Turnover Ratio
0.793Prev. Close
0.780Low
333.86KTurnover
LossP/E Static
-0.21P/B
0.00%Div Yield TTM
-207.56%ROA
8.08052wk High
1.23Volume Ratio
-59.60MNet Profit
27.07MShares
-4.7633EPS TTM
0.33Beta
-1766.94%ROE
1.01052wk Low
7.57%Amplitude
-37.38%Gross Margin
21.88MMarket Cap
-5.50Reward/Risk
7.74%Risk Rate
TradingKey Stock Score of BioXcel Therapeutics Inc
Currency: USD Updated: 2026-07-31Key Insights
BioXcel Therapeutics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 101 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.80.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioXcel Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
BioXcel Therapeutics Inc Highlights
StrengthsRisks
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Growing
The company is in a growing phase, with the latest annual income totaling USD 642.00K.
Fairly Valued
The company’s latest PE is -0.17, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.05M shares, increasing 19.34% quarter-over-quarter.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
12.800
Target Price
+1495.21%
Upside Space
BioXcel Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
5
analysts
Buy
Current Rating
12.800
Target Price
+1495.21%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
BioXcel Therapeutics Inc
BTAI
5
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
0.823
Sell
MA10
0.849
Sell
MA20
0.884
Sell
MA50
1.083
Sell
MA100
1.167
Sell
MA200
1.511
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BioXcel Therapeutics Inc Info
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Ticker SymbolBTAI
CompanyBioXcel Therapeutics Inc
CEOMehta (Vimal)
Websitehttps://www.bioxceltherapeutics.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of BioXcel Therapeutics Inc (BTAI)?
The current price of BioXcel Therapeutics Inc (BTAI) is 0.81.
What is the symbol of BioXcel Therapeutics Inc?
The ticker symbol of BioXcel Therapeutics Inc is BTAI.
What is the 52-week high of BioXcel Therapeutics Inc?
The 52-week high of BioXcel Therapeutics Inc is 8.08.
What is the 52-week low of BioXcel Therapeutics Inc?
The 52-week low of BioXcel Therapeutics Inc is 1.01.
What is the market capitalization of BioXcel Therapeutics Inc?
The market capitalization of BioXcel Therapeutics Inc is 21.96M.
Is BioXcel Therapeutics Inc (BTAI) currently rated as Buy, Hold, or Sell?
According to analysts, BioXcel Therapeutics Inc (BTAI) has an overall rating of Buy, with a price target of 12.80.
What is the Earnings Per Share (EPS TTM) of BioXcel Therapeutics Inc (BTAI)?
The Earnings Per Share (EPS TTM) of BioXcel Therapeutics Inc (BTAI) is -5.73.